Stanley T. Crooke, Ph.D., M.D, to retire from Ionis to focus on his scientific interests and n-Lorem FoundationPRNewsWire • 12/17/20
Ionis highlights achievements, commercial strategy and technology advancements at Investor DayPRNewsWire • 12/09/20
Why Is Ionis Pharmaceuticals (IONS) Up 4.6% Since Last Earnings Report?Zacks Investment Research • 12/04/20
Ionis to participate in virtual fireside chat at BMO 2020 Growth and ESG conferencePRNewsWire • 12/02/20
Ionis announces initiation of the global Phase 3 BALANCE study for AKCEA-APOCIII-LRX in patients with familial chylomicronemia syndromePRNewsWire • 12/01/20
Ionis announces AstraZeneca's initiation of the Phase 2b clinical study of its antisense medicine targeting PCSK9 to lower LDL-cholesterolPRNewsWire • 11/30/20
Ionis announces third investigational antisense medicine to treat nonalcoholic steatohepatitis (NASH) enters developmentPRNewsWire • 11/23/20
Promising new data for Ionis' antisense medicine targeting PCSK9 presented at American Heart Association (AHA) Scientific Sessions 2020PRNewsWire • 11/13/20
Ionis' pioneering antisense technology to be featured in multiple presentations at American Heart Association (AHA) Scientific Sessions 2020PRNewsWire • 11/12/20
Ionis' antisense technology to be featured during virtual RNA at the Bench and Bedside II ConferencePRNewsWire • 11/10/20
WAYLIVRA▼® (volanesorsen), the First and Only Therapy for Familial Chylomicronaemia Syndrome, an Ultra-Rare and Life-Threatening Condition, to Be Available on the NHS in ScotlandBusiness Wire • 11/09/20
Ionis and Akcea Recognize FCS Awareness Day With Global Community Efforts to Celebrate Unsung HeroesBusiness Wire • 11/06/20
Ionis Pharmaceuticals' (IONS) CEO Brett Monia on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/05/20
Ionis reports third quarter 2020 financial results and recent business achievementsPRNewsWire • 11/04/20
Ionis and Akcea announce that Pfizer has initiated a Phase 2b clinical study of vupanorsen (AKCEA-ANGPTL3-LRx)PRNewsWire • 11/03/20
Ionis and Akcea win prestigious Prix Galien Award for TEGSEDI® (inotersen) as Best Biotechnology ProductPRNewsWire • 10/30/20
Ionis' third novel antisense medicine for ALS, its first designed to treat a broad ALS population, begins clinical trialPRNewsWire • 10/22/20